Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04380519
Recruitment Status : Completed
First Posted : May 8, 2020
Results First Posted : January 24, 2022
Last Update Posted : January 24, 2022
Sponsor:
Collaborators:
Data Management 365
K-Research, LLC
Information provided by (Responsible Party):
R-Pharm ( R-Pharm International, LLC )

Brief Summary:
The primary objective of the study was to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 15 of the study.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: RPH-104 80 mg Drug: Olokizumab 64 mg Drug: Placebo Phase 2 Phase 3

Detailed Description:

The study consisted of two phases:

  • Pilot phase: the first 189 patients were randomized in three groups to receive OKZ, RPH-104 (63 patients per group), followed by an interim analysis of efficacy and safety data.
  • The main phase was the conduct of all procedures prespecified in the protocol. Based on results of interim analysis no changes were made regarding the sample size or primary efficacy endpoint.

For each patient the study included the following periods:

  • Screening period for no more than 48 hours before the start of the day of randomization (Day 1). During the screening period, an assessment was performed to determine whether the patient met the eligibility criteria;
  • Treatment period lasting from the end of the screening (considered as the beginning of the Day 1) to 23:59 of the Day 1, including randomization of the patients in the treatment groups and then a single administration of the study drug;
  • Follow-up period lasting from 00:00 of the Day 2 to 23:59 of the Day 29, including an assessment of the efficacy and safety after administration of the study drug.

Eligible patients were randomized to one of three treatment groups to receive a single subcutaneous injection: RPH-104 80 mg, OKZ 64 mg or placebo in addition to standard care for patients with COVID-19 as per the routine practice in participating facilities. Further, during the term of hospitalization, the clinical observation was performed (Day 1 - Day 15 of the Last Hospitalization Day (LHD), whichever comes first). This was followed by a follow-up period from the from Day 15 or LHD (whichever comes first) to Day 29.

Standard COVID-19 therapy, as per the institution routine practice, was permitted during the study, except the prohibited protocol medication (during the whole period of the study) and tocilizumab and sarilumab (during the first 24 hours after the study treatment administration).

In the absence of positive dynamics in the patient's condition (as per Investigator's judgement), it was possible to administrate a single dose of tocilizumab or sarilumab (in accordance with the actual recommendations), after the 24 hours from one of the study drug's administration.

On Day 15 primary endpoint of patient's clinical status (response to the study therapy) was assessed. The response to the therapy was considered as improvement of the patient's clinical status by at least 1 point on a 6-point COVID-19 scale in the absence of tocilizumab or sarilumab administration.

The last patient's visit in the study was the visit on Day 29. If the patient was discharged from the hospital earlier than Day 15 or Day 29, patient's clinical status at these visits were assessed by phone call.

The total expected duration of the study for each patient was not more than 31 days, including 48 hours of screening, 1 day of the study drug administration and 28 days of observation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 372 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)
Actual Study Start Date : April 23, 2020
Actual Primary Completion Date : July 10, 2020
Actual Study Completion Date : July 24, 2020


Arm Intervention/treatment
Experimental: RPH -104 80 mg
Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy
Drug: RPH-104 80 mg
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Experimental: Olokizumab 64 mg
Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
Drug: Olokizumab 64 mg
solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)

Placebo Comparator: Placebo
Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy
Drug: Placebo
Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package




Primary Outcome Measures :
  1. Proportion of Responders in Each Treatment Group [ Time Frame: Day 15 ]

    Proportion of patients, responded to the study therapy, in each of the treatment groups.

    A responder is a patient who has not received tocilizumab or sarilumab and who has a clinical status improvement of ≥1 point on the 6-point COVID-19 scale (where 1 is the most favorable outcome and 6 is the most undesirable outcome) 15 days after the administration of the study drug:

    1. Not hospitalized, no activity limitations.
    2. Not hospitalized, limited activity.
    3. Hospitalized, not requiring supplemental oxygen.
    4. Hospitalized, supplemental oxygen with independent breathing.
    5. Hospitalized; mechanical ventilation (invasive/non-invasive) or Extracorporeal membrane oxygenation (ECMO).
    6. Death.


Secondary Outcome Measures :
  1. Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale [ Time Frame: from Day 2 until Day 15, Day 29 ]

    Changes of patients' clinical status on a 6 points ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) over time.

    The 6-point ordinal scale included the following categories:

    1. Not hospitalized, no activity limitations.
    2. Not hospitalized, limited activity.
    3. Hospitalized, not requiring supplemental oxygen.
    4. Hospitalized, supplemental oxygen, with independent breathing.
    5. Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.
    6. Death.

  2. The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab [ Time Frame: Day 29 ]

    The proportion of patients with an improvement in clinical status by 2 or more points on the 6-point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab.

    The 6-point ordinal scale included the following categories:

    1. Not hospitalized, no activity limitations.
    2. Not hospitalized, limited activity.
    3. Hospitalized, not requiring supplemental oxygen.
    4. Hospitalized, supplemental oxygen, with independent breathing.
    5. Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.
    6. Death.

  3. The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study [ Time Frame: from Day 2 until the Day 29 ]
    The proportion of patients who received tocilizumab or sarilumab for COVID-19 during the study

  4. Mortality Rate During the Study [ Time Frame: from Day 1 until Day 29 ]
    Mortality rate over the follow-up period of the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. The presence of a voluntarily signed and dated Patient Informed Consent Form for participation in this study, or a record of an Medical Consilium decision justifying patient's participation in case of patient is unable to state his/her will.
  2. Having either of the following COVID-associated respiratory syndromes:

    • pneumonia with oxygenation saturation SpO2 ≤93% (on room air) or respiratory rate greater than 30/min;
    • Acute respiratory distress syndrome (ARDS) ( PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 315 if PaO2 is not available).
  3. COVID-19 diagnosis based on:

    • laboratory-confirmed SARS-CoV-2 infection as determined by Polymerase Chain Reaction method (PCR).

OR

• Bilateral changes in the lungs typical for COVID-19, based on chest computed tomography results.

Exclusion criteria:

  1. A history of hypersensitivity to the study drugs (RPH-104 and/or OKZ), and/or their components.
  2. The presence of any of the following laboratory abnormalities:

    • absolute neutrophil counts < 0.5 x 10^9 L
    • white blood cell count < 2 x 10^9 L
    • platelet count <50 x 10^9 L
    • Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) ≥ 3.0 x Upper Limit of Normal (ULN)
  3. Severe renal failure: creatinine clearance < 30 mL/min
  4. Septic shock (vasopressors are required to maintain mean arterial pressure ≥ 65 mm Hg and lactate ≥ 2 mmol/L in the absence of hypovolemia)
  5. The disease progresses to death over the next 24 hours, regardless of treatment, according to Investigator.
  6. Perforation of the gastrointestinal tract, a history of diverticulitis.
  7. Administration of plasma from COVID-19 convalescent donors within 4 weeks before study enrollment and/or planned administration during the study.
  8. Recent (less then 5 half-lives) administration of tocilizumab or sarilumab;
  9. Recent (less then 5 half-lives) or planned during the current study period use of the following drugs:

    • biologics (except RPH-104 or OKZ) with immunosuppressive effect, including, but not limited to: Interleukin-1 (IL-1) inhibitors (anakinra, rilonacept, canakinumab), IL- 6 inhibitors (except tocilizumab and sarilumab), IL-17A inhibitors (secukinumab), tumor necrosis factor α (TNFα) inhibitors (infliximab, adalimumab, etanercept, etc.), antiB-cell drugs, etc.
    • other immunosuppressive drugs (with the exception of methotrexate in a dose of up to 25 mg/week), including, but not limited to:

      1. high doses of glucocorticoids (equivalent to prednisolone > 1 mg/kg) orally or parenterally;
      2. Janus kinase (JAK) kinase inhibitors; cyclophosphamide, etc.
  10. Concurrent participation in another clinical trial.
  11. Pregnancy, breastfeeding.
  12. A history of active tuberculosis, or active tuberculosis suspected by the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04380519


Locations
Layout table for location information
Russian Federation
Private healthcare institution "Clinical Hospital" Russian Railways-Medicine named after N. A. Semashko"
Moscow, Russian Federation, 109386
State Budget Healthcare Institution "City Clinical Hospital № 15 named after O.M. Filatov" of Moscow City Healthcare Department
Moscow, Russian Federation, 111539
Federal State Budgetary Institution "Federal Center for Cerebrovascular Pathology and Stroke" of the Ministry of Health of the Russian Federation
Moscow, Russian Federation, 117997
Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University)
Moscow, Russian Federation, 119991
Federal State Autonomous Education Institution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of the Russian Federation (Sechenov University)
Moscow, Russian Federation, 119991
Federal State Budgetary Institution "Central Clinical Hospital with Polyclinic" of Administrative Directorate of the President of the Russian Federation
Moscow, Russian Federation, 121359
Federal State Budget Institution "National Medicine Research Center on Cardiology" By Ministry of Healthcare of Russian Federation
Moscow, Russian Federation, 121552
State Budget Institution of Healthcare "City Clinical Hospital #52", Moscow City Healthcare Department
Moscow, Russian Federation, 123182
State budgetary healthcare institution City Clinical Hospital named after S.I. Spasokukotsky Department of Health of the city of Moscow City Clinical Hospital No. 50
Moscow, Russian Federation, 127206
Moscow State Budget Institution of Healthcare "Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"
Moscow, Russian Federation, 129090
АО "State Company "Medsi" based on Clinical Hospital №1"
Moscow, Russian Federation, 143442
Federal State Budgetary Educational Institution of Higher Education "Volga Research Medical University" of the Ministry of Health of the Russian Federation
Nizhniy Novgorod, Russian Federation, 603950
Saint-Petersburg State Budget Institution of Healthcare "City Hospital №40"
Saint Petersburg, Russian Federation, 197706
Federal Budgetary State Healthcare Institution "National Medical Research Center named after B.A. Almazov"
Saint-Petersburg, Russian Federation, 197341
Budgetary Health Institution Voronezh Regional Clinical Hospital №1
Voronezh, Russian Federation, 394066
State Budget Healthcare Institution of Yaroslavl Region "Yaroslavl Region Clinical Hospital of War Veterans"
Yaroslavl, Russian Federation, 150047
Sponsors and Collaborators
R-Pharm International, LLC
Data Management 365
K-Research, LLC
Investigators
Layout table for investigator information
Study Director: Mikhail Samsonov Chief Medical Officer, R-Pharm
  Study Documents (Full-Text)

Documents provided by R-Pharm ( R-Pharm International, LLC ):
Layout table for additonal information
Responsible Party: R-Pharm International, LLC
ClinicalTrials.gov Identifier: NCT04380519    
Other Study ID Numbers: CL04041078
First Posted: May 8, 2020    Key Record Dates
Results First Posted: January 24, 2022
Last Update Posted: January 24, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by R-Pharm ( R-Pharm International, LLC ):
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
2019-nCoV
2019 novel coronavirus
Respiratory disease
lung disease
COVID-19
coronavirus
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Severe Acute Respiratory Syndrome
Infections
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases